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Abstract
Background: Clevudine is a nucleoside analog reverse transcriptase inhibitor that exhibits potent antiviral activity
against hepatitis B virus (HBV) without serious side effects. However, mitochondrial myopathy has been observed in
patients with chronic HBV infection taking clevudine. Moreover, the development of diabetes was recently reported
in patients receiving long-term treatment with clevudine. In this study, we investigated the effects of clevudine on
mitochondrial function and insulin release in a rat clonal b-cell line, INS-1E.
Methods: The mitochondrial DNA (mtDNA) copy number and the mRNA levels were measured by using
quantitative PCR. MTT analysis, ATP/lactate measurements, and insulin assay were performed.
Results: Both INS-1E cells and HepG2 cells, which originated from human hepatoma, showed dose-dependent
decreases in mtDNA copy number and cytochrome c oxidase-1 (Cox-1) mRNA level following culture with
clevudine (10 μM-1 mM) for 4 weeks. INS-1E cells treated with clevudine had reduced total mitochondrial activities,
lower cytosolic ATP contents, enhanced lactate production, and more lipid accumulation. Insulin release in
response to glucose application was markedly decreased in clevudine-treated INS-1E cells, which might be a
consequence of mitochondrial dysfunction.
Conclusions: Our data suggest that high-dose treatment with clevudine induces mitochondrial defects associated
with mtDNA depletion and impairs glucose-stimulated insulin secretion in insulin-releasing cells. These findings
partly explain the development of diabetes in patients receiving clevudine who might have a high susceptibility to
mitochondrial toxicity.
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Background
Chronic infection with hepatitis B virus (HBV) fre-
quently leads to serious liver disease such as cirrhosis,
fulminant hepatic failure, and hepatocellular carcinoma
[1]. Several antiviral drugs have been developed and
prescribed for HBV infection. Commonly used antiviral
therapies are nucleoside analog reverse transcriptase
inhibitors (NRTIs) including entecavir, lamivudine, and
telbivudine. NRTIs undergo intracellular and
intramitochondrial phosphorylation into active tripho-
sphates that are capable of inhibiting HIV reverse tran-
scriptase (RT) [2]. However, these drugs have side
effects such as lipodystrophy, neuropathy, myopathy,
and liver steatosis, all of which are related to mito-
chondrial toxicity. In vitro and in vivo studies have
shown that some NRTIs inhibit DNA polymerase-g,a
nuclear-encoded polymerase important for mitochon-
drial DNA (mtDNA) replication [3,4]. Depletion of
mtDNA induced by NRTIs may attenuate mitochon-
drial oxidative phosphorylation, which could limit their
clinical use.
Clevudine (1-(2-deoxy-2-fluoro-b-L-arabinofuranosyl)
thymine) is an NRTI that exhibits potent and sustained
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mitochondrial structure and function compared to those
of other NRTIs [2,5]. However, long-term therapy for
more than one year results in the development of con-
siderable drug resistance and skeletal myopathy [6-9].
Muscle biopsies from patients with myopathy as a com-
plication of clevudine treatment revealed severe necrosis
with cytochrome c oxidase (COX)-negative ragged red
fibers, the typical phenotype of mitochondrial myopathy
[7,10]. Clevudine-induced myopathy developed in
approximately 4-5% of patients and was usually reversi-
ble after discontinuation of clevudine [9].
It is well known that mitochondria play a critical role
in nutrient-stimulated insulin secretion, as well as in
insulin actions at target cells [11]. Recently, a patient
who developed diabetes mellitus after clevudine treat-
ment was reported [12]. We hypothesized that the mito-
chondrial dysfunction invoked by clevudine treatment
could be a precipitating factor in diabetogenesis. Until
now, the majority of in vitro studies for antiviral agent
toxicities have been performed in different cell types,
yielding conflicting results [13-15]. Insulin-secreting
cells are highly specialized fuel sensors that maintain
blood glucose level in the body by monitoring the ATP/
ADP ratio, which is strictly regulated by mitochondrial
oxidative phosphorylation. Thus, insulin-secreting cells
are an appropriate model system for identification of
mitochondrial toxicity and its functional consequences
following antiviral therapy. In this study, we investigated
the effects of clevudine exposure on mtDNA content,
mitochondrial function, and metabolism-secretion cou-
pling in insulin-releasing cells to elucidate the mechan-
ism underlying the reversible diabetes observed in
clevudine-treated patients.
Methods
Cell culture and drugs
Clevudine was purified from Revovir
® tablets (Bukwang
Pharm. Co., Seoul, Korea). The amount of harvested cle-
vudine was analyzed using HPLC (Agilent G1315B UV
Diode array detector, AD, Santa Clara, CA, USA). A sin-
gle peak with the expected amount of clevudine was
m e a s u r e db a s e do nt h ek n o w nw e i g h to fo n et a b l e t .
INS-1E cell, a clonal pancreatic b-cell line received from
P r o f .C l a e sB .W o l l h e i m ,w e r ec u l t u r e di nc o m p l e t e
medium composed of RPMI 1640 (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal calf serum, 1
mM sodium pyruvate, 50 μM 2-mercaptoethanol, 2 mM
glutamine, 10 mM HEPES, 100 units/ml penicillin, and
100 μg/ml streptomycin. HepG2 cells, a human hepa-
toma cell line, were grown in DMEM medium (Invitro-
gen) containing 5.6 mM glucose, 4 mM L-glutamine
and 1 mM sodium pyruvate. For the following
experiments, cells were cultured with or without clevu-
dine for 4 weeks.
Quantitative PCR
Total DNA or RNA was isolated and purified from INS-
1E and HepG2 cells using DNeasy or RNeasy kits (Qia-
gen, Valencia, CA, USA), respectively. To obtain cDNA,
reverse transcription (RT) was performed with oligo-dT
(Applied Biosystems, Foster City, CA, USA) using reverse
transcriptase (Promega, Madison, WI, USA). For PCR
amplification, sequence-specific oligonucleotide primers
for the genes of interest were designed (Bioneer, Daejeon,
Korea) based on rat and human sequences in the Gen-
Bank database (Table 1). Quantitative real-time PCR
using SYBR Green PCR Master Mix (Applied Biosystems)
was performed in an ABI PRISM 7900HT Sequence
Detection System (Applied Biosystems) according to the
manufacturer’s protocol. All amplifications were followed
by melting curve analysis. The b-actin was used as the
reference gene, and relative abundance of DNA or
mRNA in clevudine-treated cells was normalized to that
level in control cells calculated by using 2
-ΔΔCt method.
MTT assay
3-(4,5-dimethylhioazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was purchased from Sigma (St. Louis,
MO, USA). INS-1E cells seeded onto a 96-well plate
Table 1 Primers for quantitative PCR
Name Primer sequence Accession code product
size
rat b-
actin
+ ATGGTGGGTATGGGTCAGAA NM_031144.2 100 bp
- TCCATATCGTCCCAGTTGGT
rat
Cox1
+ GGAGCAGTATTCGCCATCAT NC_001665 90 bp
- GTGGGCTTTTGCTCATGTGT
rat
PGC1a
+ GGCACATCTGTTCTTCCACA NM_031347.1 110 bp
- TTCCTGGTCTTGGAGCTGTT
rat
NRF1
+ GGACAGCAAGCCATTGTTCT NM_001100708.1 98 bp
- TACTTGCGCACCACATTCTC
rat
Tfam
+ GCTGAGTGGAAGGTGTACAAAG NM_031326.1 85 bp
- CTTCCTTCTCTAAGCCCATCAG
rat SDH + TCTTTCCTACCCGCTCACAT NM_130428.1 90 bp
- AATGCCATCTCCAGTTGTCC
human
b-actin
+ AAGTTCACAATGTGGCCGAG NM_001101.3 98 bp
- ATGGCAAGGGACTTCCTGTA
human
Cox1
+ CACACTCCACGGAAGCAATA NC_012920.1 82 bp
- GCCACCTACGGTGAAAAGAA
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4 cells/well) were incubated with MTT (50 μg/
well) for 2 hrs, and then the medium was discarded and
replaced with dimethylsulfoxide (100 μl/well). The
absorbance of each well was measured at 570 nm using
an enzyme-linked immunosorbent assay (ELISA) reader,
after background subtraction at 650 nm.
Cytochrome c oxidase (COX) activity measurement
INS-1E cells were harvested and incubated with isosmo-
tic medium [16] containing 0.2% triton X-100 at 30°C
for 2 min. Enzymatic activity of COX was measured
spectrophotometrically at 550 nm based on previous
reports [16,17].
ATP and lactate measurements
INS-1E cells seeded onto 24-well plates (3 × 10
5 cells/
well) were preincubated with glucose-free medium for 2
hrs prior to incubation with KRBH solution (135 mM
NaCl, 3.6 mM KCl, 2 mM NaHCO3,0 . 5m MN a H 2PO4,
0.5 mM MgSO4,1 . 5m MC a C l 2, 10 mM HEPES, pH 7.4)
containing 2.8 mM glucose for 30 min. The cells were
then stimulated for 15 min with KRBH buffer at a low
(2.8 mM) or high (16.7 mM) glucose concentration. The
A T Pc o n t e n ti nt h ec e l ll y s a t e( R o c h eH S - I IB i o l u m n i s -
cence kit, Mannheim, Germany) and the lactate level in
the cell supernatant (Biovision #K607-100, Mountain
View, CA, USA) were measured as described previously
[18]. Measurement of the protein concentration in cell
lysates was performed using the Bradford assay.
Oil red staining
INS-1E cells on coverslip were treated with bovine
serum albumin (BSA) or oleate, a monounsaturated
fatty acid for 24 hours. After fixation with 10% formalin,
cells were washed with 60% isopropanol and dried at
room temperature. Cells were incubated with Oil Red O
(Sigma, St. Louis, MO, USA) for 10 min, and then coun-
terstained with hematoxylin.
Insulin measurement
INS-1E cells were seeded and cultured as for ATP and
lactate measurement. For insulin measurement, 0.1%
BSA was included in the KRBH solution, and the cells
were stimulated with low or high concentrations of glu-
cose for 30 min, as described previously [18]. Insulin
levels in supernatant and cell extracts were measured
using a rat insulin enzyme immunoassay kit (Shibayagi
Co., Gunma, Japan).
Data analysis
All data are presented as mean ± SEM, and the statisti-
cal significance was determined using One-way ANOVA
or Student’s t test.
Results
Effects of clevudine on mtDNA copy number and mRNA
levels of mtDNA encoded genes
INS-1E cells were cultured with different concentrations
of clevudine for 4 weeks and the in vitro effects on
mtDNA replication and translation were measured.
Treatment with clevudine (10 μM to 1 mM) reduced the
mtDNA copy number in a dose-dependent manner (Fig-
ure 1A). Two weeks treatment with clevudine induced
39% reduction of mtDNA level (n = 3), which was smal-
ler than four weeks treatment (51%). The mRNA levels
of mtDNA-encoded Cox-1 were also dose-dependently
attenuated by clevudine (Figure 1B). Interestingly, we
observed upregulation of PPAR- g coactivator 1a (PGC-
1a), mitochondrial transcription factor A (Tfam), and
nuclear respiratory factor 1 (NRF1)i nc l e v u d i n e - t r e a t e d
INS-1E cells. Upregulation of these transcription factors
could be a nuclear response to mitochondrial dysfunction
[3]. Succinate dehydrogenase (SDH), a nuclear-encoded
mitochondrial enzyme, was also upregulated by clevu-
dine-treatment (Figure 1C). We next examined the
effects of clevudine on the levels of mtDNA and RNA in
the human hepatoma cell line HepG2, major target cells
of insulin action. Clevudine showed suppressive effects
on mtDNA replication and transcription in HepG2 cells,
similar to the effect in INS-1E cells (Figures 1D and 1E).
Mitochondrial dysfunction induced by clevudine
The amount of formazan reaction product formed in the
MTT assay reflects the total mitochondrial enzymatic
activity in each well. INS-1E cells treated with or with-
out clevudine for 4 weeks were seeded 48 hrs before the
MTT assay. Exposure to clevudine decreased the MTT
absorbance (71% by 100 μMa n d5 6 %b y1m M ,F i g u r e
2A). However, we observed that there was no significant
difference in protein amount between control cells (59 ±
3 μg; n = 17) and cells incubated with 100 μM( 6 2±4
μg; n = 17) or 1 mM clevudine (59 ± 3 μg; n = 17) for
48 hours after seeding (3 × 10
5 cells). This result implies
that reduction of MTT signal by clevudine might be
resulted from decreased mitochondrial reducing capa-
city. To demonstrate the functional significance of
decreased Cox1 mRNA, we performed the enzymatic
activity measurement of cytochrome c oxidase (Cox)
based on previous reports [16,17]. We observed the
reduced Cox activity of clevudine (1 mM)-treated cells
compared to that of control INS-1E cells (Figure 2B).
We measured the cellular contents of ATP in control
and clevudine-treated INS-1E cells using a biolumines-
cence method after incubation with low (2.8 mM) or high
(16.7 mM) concentrations of glucose for 15 min. As shown
in Figure 3A, cells cultured with 1 mM clevudine had
lower cytosolic ATP level in both low and high glucose
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INS-1E cells was markedly elevated by incubation with glu-
cose for 15 min (Figure 3B). The glucose-induced lactate
production was increased in cells treated with 1 mM clevu-
dine compared to that in control cells (Figure 3B).
One of the metabolic consequences of mitochondrial
dysfunction is an impairment of fatty acid oxidation,
thus leading to lipid accumulation [19,20]. To detect the
lipid droplet in cytosol, we performed Oil-red O staining
to control and clevudine-treated cells. Without exogen-
ous fatty acid loading, there was no significant difference
between two groups. When we incubated cells with a
mono-unsaturated fatty acid, 0.7 mM oleate, clevudine-
treated cells showed a pronounced lipid accumulation,
which was much less in control cells (Figure 4).
Inhibition of glucose-stimulated insulin secretion by
clevudine
To identify whether clevudine-induced mitochondrial
dysfunction affects insulin secretory activity, we
measured the released and cellular contents of insulin
v i aa ne n z y m ei m m u n o a s s a y .The cellular insulin con-
tents were not significantly different between control
INS-1E cells (816 ± 167 ng/well) and cells treated with
c l e v u d i n e( 1m M )f o r4w e e k s( 7 6 9±1 7 0n g / w e l l ) .
After incubation for 30 min with low (2.8 mM) or high
(16.7 mM) concentrations of glucose, the released insu-
lin was normalized to the cellular content and expressed
as a percentage of the content released. We observed
that high concentration glucose stimulated the release of
insulin by 5.1-fold in control cells but by only 3.1-fold
and 1.9-fold in cells treated with 100 μM and 1 mM cle-
vudine for 4 weeks, respectively (Figure 3). There was
no difference in % insulin releases induced by low con-
centration glucose between the control and clevudine-
treated groups (Figure 5A). We observed that the glu-
cose-stimulated insulin secretion was completely abol-
ished by the treatment with oligomycin (0.75 μg/ml), a
mitochondrial ATP synthase inhibitor (Figure 5B). This
result demonstrates the cause-effect relationship
Figure 1 Effects of clevudine on mitochondrial DNA copy number and mRNA levels of mitochondria-related genes. The mitochondrial
DNA copy number and the mRNA levels of mtDNA-encoded or nuclear DNA-encoded genes were measured using quantitative PCR. Clevudine
reduced the expressions of mtDNA (A & D) and cytochrome c oxidase-1 (Cox-1) mRNA (B & E) in the rat clonal b-cell line INS-1E and in the
human hepatoma cell line HepG2 in a dose-dependent manner. Nuclear-encoded genes related to mitochondrial biogenesis such as PPAR-g
coactivator 1a (PGC-1a), mitochondrial transcription factor A (Tfam), and nuclear respiratory factor 1 (NRF1) were upregulated by clevudine
treatment (C). Succinate dehydrogenase (SDH) was also upregulated by clevudine (C). Data presented are means ± SEM. The number of
experiments is shown in parenthesis. *, **, and *** denote p < 0.05, p < 0.01, and p < 0.001, respectively.
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secretion.
Discussion
In pancreatic b-cells, mitochondria are of particular
importance in the regulation of insulin secretion
because they produce ATP as well as other coupling
factors which link nutrient metabolism and insulin exo-
cytosis [11]. mtDNA-depleted b-cell lines show com-
plete absence of nutrient-stimulated insulin secretion
[21]. Patients with mtDNA mutations develop diabetes,
accounting for up to 1% of the total number of diabetic
patients [22]. Moreover, postmortem islets from type 2
diabetes patients display functional deterioration of
Figure 2 High-dose clevudine decreased the mitochondrial activities in INS-1E cells. (A) Clevudine reduced the MTT signal, which reflects
total mitochondrial activity within each well. (B) Clevudine decreased the enzymatic activity of cytochrome c oxidase (COX). Data are presented
as means ± SEM. The number of experiments is shown in parenthesis. * and ** denote p < 0.05 and p < 0.01, respectively.
Figure 3 High-dose clevudine decreased ATP level and increased lactate production in INS-1E cells. Cytosolic ATP level was reduced (A),
but glucose-stimulated lactate production was enhanced (B) in 1 mM clevudine-treated cells. Data are presented as means ± SEM. * denotes p
< 0.05.
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mitochondrial function in pancreatic b-cells might affect
metabolism-secretion coupling and diabetogenesis.
The present study showed that the effective anti-HBV
agent clevudine has a negative effect on the copy num-
ber and transcription of mtDNA in insulin-releasing
cells and hepatoma cells. The reduced expressions of
mtDNA-encoded proteins lead to attenuation of mito-
chondrial function. In insulin-releasing cells, clevudine-
induced mitochondrial dysfunction can elicit defective
insulin secretion in response to substrates for mitochon-
drial metabolism. To our knowledge, this is the first
demonstration that an antiviral agent can impair nutri-
ent-stimulated insulin secretion as a result of
Figure 4 Effects of clevudine on lipid accumulation in INS-1E cells. INS-1E cells on coverslip were treated with 0.7 mM oleate or bovine
serum albumin (BSA) for 24 hours, and stained Oil Red O with hematoxylin. Clevudine (1 mM)-treated cells showed a pronounced lipid
accumulation (red droplets) upon oleate incubation, which was much less in control cells.
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dency on mitochondrial function in metabolism-secre-
tion coupling, insulin-secreting cells provide a useful
model to investigate the functional consequences of
drug-induced mitochondrial toxicity.
NRTIs are widely used to treat various viral diseases
such as acquired immunodeficiency syndrome (AIDS)
and hepatitis B [24]. However, in vitro studies showed
that NRTIs can alter mtDNA content by inhibiting
DNA polymerase-g [25]. Moreover, myopathy accompa-
nied by mtDNA depletion has been reported in NRTI-
treated patients [4]. Clevudine treatment has also been
associated with the development of mitochondrial com-
plications. In contrast to early studies [2], depletion of
mtDNA in skeletal muscle has been observed in patients
treated with clevudine [7,26]. Typical histological fea-
tures of mitochondrial myopathy and abnormal mito-
chondrial morphology were displayed in tissues from
patients with increased lactate dehydrogenase and lac-
tate levels [8,10]. Although the incidence of clevudine-
induced myopathy was reported to be low (~5%) [9], a
substantial proportion (~14.5%) of clevudine-treated
patients have been found to experience symptoms,
signs, and laboratory abnormalities relevant to clevu-
dine-induced myopathy [27].
To directly confirm the effects of clevudine on mito-
chondrial function, we cultured cells with medium con-
taining different concentrations of clevudine for 4
weeks. Clevudine markedly decreased the MTT signal
without significant changes in cellular protein implying
the diminished enzyme activities for reduction of MTT.
Since MTT assay is not specific to evaluate mitochon-
drial function, measurement of oxygen consumption
rate or citrate synthase activity could provide more con-
crete evidence to prove the mitochondrial defects. Con-
sistent with mtDNA depletion, COX activity and
cellular ATP content were reduced. Decreased mito-
chondrial fatty acid oxidation could induce triglyceride
accumulation [19]. To avoid lipotoxic effects of palmi-
tate in insulin-secreting cells [28], we loaded unsatu-
rated fatty acid oleate for 24 hours, which elicited a
marked increase of lipid accretion within clevudine-trea-
ted cells. The inhibitory effect of clevudine on insulin
secretion was more sensitive than the effect on ATP
level. We can speculate that the treatment of 100 μM
clevudine elicited significant reduction of ATP/ADP
ratio which is the main signal for closing ATP-sensitive
K
+ channel and insulin exocytosis.
We also observed some compensatory responses to
reduced mtDNA copy number and its functional conse-
quences. First, PGC-1a and its downstream transcrip-
tional factors, NRF-1 and Tfam, were upregulated by
clevudine. Second, nuclear DNA-encoded succinate
dehydrogenase was also upregulated, which has already
been observed in muscle of patients suffering from cle-
vudine-induced myopathy [10]. Third, lactate production
was modestly increased in association with diminished
ATP content. Pancreatic b-cells and clonal b-cell lines
are known to have very low lactate dehydrogenase
levels, which contribute to their dependency on mito-
chondrial function. The increase in lactate production
observed in our study also demonstrates that clevudine
imposes selective defects on mitochondria rather than
overall cytotoxicity.
In our study, mtDNA copy number in clevudine (1
mM)-treated cells was decreased to half of that in
Figure 5 Clevudine inhibited glucose-stimulated insulin secretion. Released insulin and cellular insulin content were measured using an
enzymatic immunoassay after incubation with Krebs buffer containing 2.8 mM or 16.7 mM glucose for 15 min. Glucose-stimulated insulin
secretion was impaired by clevudine incubation (A), as well as by inhibiting mitochondrial ATP synthase with oligomycin (B). Insulin release was
normalized to the insulin content. Data presented are mean ± SEM. ** denotes p < 0.01.
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mitochondrial dysfunction mtDNA level should fall
below 60% which was named as ‘phenotypic threshold’
[29]. This can be explained by genetic and functional
complementation at the levels of transcription, transla-
tion, enzyme activity and cell activity. Several investiga-
tors showed that NRTI such as zidovudine and
stavudine can also induce mitochondrial dysfunction
independent from lack of mtDNA [20,30]. Thus, we
cannot exclude the possibility that clevudine could be
involved in multiple site of inhibition of mitochondrial
function in addition to the effects of mtDNA depletion.
Niu et al. [31] suggested that the intracellular level of the
triphosphate form of clevudine in cells exposed to 1 μM
extracellular clevudine approximates the plasma level in
patients receiving a 30 mg dose. Our results indicated that
impairments in mitochondrial function and insulin secre-
tion are elicited only by high concentrations of clevudine
(> 100 μM). This means that clevudine would minimally
affect mitochondrial function within the therapeutic con-
centration range. It is noteworthy, however, that mutations
or polymorphisms of DNA polymerase-g were identified in
NRTI-treated patients with mitochondrial complications
[32]. This suggests that genetic alterations in DNA poly-
merase-g are not normally deleterious, but that certain
conditions such as NRTI treatment may push mitochon-
drial activity below the clinical threshold, causing patho-
genic dysfunction [33]. Differences in genetic susceptibility
to mitochondrial toxicity could be one explanation for
why a limited proportion of patients receiving clevudine
have complications including myopathy.
Clevudine-induced depletion of mtDNA is not
restricted to insulin-secreting cells but is also observed
in cultured hepatoma cells or muscle tissue from
patients [7,26]. Mitochondrial dysfunction in insulin tar-
get tissues such as liver and muscle could result in insu-
lin resistance and diabetes [34]. In addition to defects in
insulin secretion, decreased sensitivity in insulin target
cells can also participate in diabetogenesis in patients
receiving clevudine who might have a high susceptibility
to mitochondrial toxicity. Interestingly, several reports
have shown that NRTI induces intramitochondrial pyri-
midine deficiency which may aggravate mtDNA deple-
tion and mitochondrial dysfunction [35,36]. They also
discovered that uridine supplementation attenuates stea-
tohepatitis or mitochondrial myopathy induced by
NRTI. Further studies concerning the effects of NRTIs
on mitochondrial function in different cell types may
help us understanding these intractable complications
and develop novel antiviral agents.
Conclusions
In summary, clevudine, used as an antiviral agent
against chronic hepatitis B, significantly decreased the
mtDNA copy number at higher doses compared to
therapeutic concentration. Mitochondrial dysfunction
due to depleted mtDNA and defective ATP synthesis
in insulin-releasing cells, consequently led to the
impairment of glucose-stimulated insulin secretion.
Clevudine-induced mitochondrial dysfunction may
contribute to diabetogenesis among clevudine-treated
patients who might be more susceptible to mitochon-
drial toxicity.
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